Sectors & Industries HealthcareDiagnostics & Research
Best Diagnostic & Research Stocks to Buy Now (2025)
Top diagnostic & research stocks in 2025 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best diagnostic & research stocks to buy now. Learn More.

Industry: Diagnostics & Research

Overview Zen Rating Price Value Growth Financials Momentum Sentiment

Diagnostics & Research is Zen Rated B and is the 52nd ranked industry out of 145 stock market industries

Ticker	Company	Market Cap	Shares	Institutional %	Insider %	Net Insider (L12M)	Net Insider (L3M)
QGEN	QIAGEN NV	$9.38B	222,290,848	80.44%	0.00%
ILMN	ILLUMINA INC	$12.12B	158,400,000	93.36%	6.64%	Net Selling	Net Selling
A	AGILENT TECHNOLOGIES INC	$30.35B	285,102,717	88.41%	1.23%	Net Buying	Net Buying
WAT	WATERS CORP	$20.31B	59,410,941	92.54%	7.46%	Net Selling	Net Selling
MTD	METTLER TOLEDO INTERNATIONAL INC	$22.10B	20,916,459	94.26%	4.64%	Net Selling	Net Selling
DHR	DANAHER CORP	$140.78B	715,669,594	75.47%	24.53%	Net Selling	Net Selling
CDNA	CAREDX INC	$839.11M	55,680,549	77.78%	22.22%	Net Selling	Net Selling
IDXX	IDEXX LABORATORIES INC	$38.34B	81,328,233	88.11%	1.74%	Net Selling	Net Selling
LH	LABCORP HOLDINGS INC	$20.20B	83,700,000	92.85%	1.54%	Net Selling	Net Selling
DGX	QUEST DIAGNOSTICS INC	$19.80B	111,635,472	88.44%	1.77%	Net Selling	Net Selling
CRL	CHARLES RIVER LABORATORIES INTERNATIONAL INC	$5.98B	51,141,607	96.87%	3.13%	Net Selling	Net Buying
CSTL	CASTLE BIOSCIENCES INC	$550.61M	28,514,109	85.52%	14.48%	Net Selling	Net Selling
IQV	IQVIA HOLDINGS INC	$26.61B	176,100,000	52.53%	47.47%	Net Selling	Net Buying
SHC	SOTERA HEALTH CO	$3.43B	283,855,074	66.68%	33.32%	Net Selling	Net Selling
RVTY	REVVITY INC	$11.17B	120,187,286	92.65%	2.65%	Net Selling	Net Selling
MEDP	MEDPACE HOLDINGS INC	$8.69B	28,741,609	27.80%	72.20%	Net Buying	Net Buying
MYGN	MYRIAD GENETICS INC	$651.03M	91,309,064	92.22%	7.78%	Net Selling	Net Selling
XGN	EXAGEN INC	$109.89M	17,898,098	33.76%	62.41%	Net Selling	Net Selling
FONR	FONAR CORP	$81.01M	6,585,978	47.25%	3.58%
NTRA	NATERA INC	$20.46B	135,186,184	79.39%	20.61%	Net Selling	Net Selling
FLGT	FULGENT GENETICS INC	$531.81M	30,829,454	45.21%	54.79%	Net Selling	Net Selling
MYNZ	MAINZ BIOMED NV	$6.91M	2,319,353	10.58%	0.00%
TWST	TWIST BIOSCIENCE CORP	$2.25B	59,651,142	87.77%	12.23%	Net Selling	Net Selling
TMO	THERMO FISHER SCIENTIFIC INC	$158.41B	377,261,182	89.34%	0.89%	Net Selling	Net Selling
GH	GUARDANT HEALTH INC	$6.05B	123,888,045	65.49%	34.51%	Net Selling	Net Selling
DRIO	DARIOHEALTH CORP	$30.05M	41,567,016	18.66%	39.45%	Net Buying
NEO	NEOGENOMICS INC	$934.32M	128,694,503	71.82%	28.18%	Net Selling
ICLR	ICON PLC	$11.54B	79,464,252	95.64%	0.00%
BDSX	BIODESIX INC	$76.78M	145,978,410	40.19%	52.74%	Net Buying	Net Selling
ADVB	ADVANCED BIOMED INC	$41.33M	21,640,000	0.00%	0.00%
GRAL	GRAIL INC	$1.10B	33,895,246	72.71%	27.29%	Net Buying	Net Buying
EXAS	EXACT SCIENCES CORP	$8.90B	188,637,673	96.73%	3.27%	Net Selling	Net Selling
STIM	NEURONETICS INC	$293.53M	65,814,512	11.47%	65.64%	Net Buying	Net Buying
OPK	OPKO HEALTH INC	$1.07B	793,052,803	20.04%	79.96%	Net Buying	Net Buying
APDN	APPLIED DNA SCIENCES INC	$1.00M	1,103,770	9.60%	90.40%
LAB	STANDARD BIOTOOLS INC	$420.67M	378,986,362	55.81%	44.19%	Net Buying	Net Buying
OCX	ONCOCYTE CORP	$88.66M	28,599,285	9.32%	90.68%	Net Buying	Net Buying
PSNL	PERSONALIS INC	$340.70M	88,263,269	58.46%	40.94%	Net Buying
RDNT	RADNET INC	$3.87B	74,041,715	67.42%	32.58%	Net Selling	Net Buying
NOTV	INOTIV INC	$67.06M	33,869,269	26.04%	39.97%	Net Buying	Net Selling
SERA	SERA PROGNOSTICS INC	$110.35M	37,663,562	48.07%	25.83%	Net Selling	Net Selling
ACRS	ACLARIS THERAPEUTICS INC	$148.93M	107,918,821	57.60%	42.40%	Net Buying	Net Selling
NEOG	NEOGEN CORP	$1.12B	217,038,267	98.57%	1.43%	Net Buying	Net Buying
VNRX	VOLITIONRX LTD	$47.02M	96,543,744	19.36%	37.79%	Net Buying	Net Buying
TRIB	TRINITY BIOTECH PLC	$6.09M	153,310,284	1.70%	0.00%
PRPH	PROPHASE LABS INC	$13.53M	41,879,017	5.78%	24.64%
STRR	STAR EQUITY HOLDINGS INC	$7.21M	3,205,832	0.95%	99.05%	Net Buying
MDXH	MDXHEALTH SA	$8.61M	49,497,334	23.84%	76.16%
PRPO	PRECIPIO INC	$9.55M	1,504,312	0.30%	99.70%	Net Buying	Net Buying
MMA	MIXED MARTIAL ARTS GROUP LTD	$8.81M	10,282,686	0.29%	0.00%
BIAF	BIOAFFINITY TECHNOLOGIES INC	$8.67M	18,255,824	2.93%	26.34%
PMAX	POWELL MAX LTD	$5.88M	14,688,269	0.00%	0.00%
XWEL	XWELL INC	$4.10M	5,261,024	1.49%	98.51%	Net Buying
CHEK	CHECK-CAP LTD	$4.62M	5,851,042	2.33%	0.00%
BNR	BURNING ROCK BIOTECH LTD	$29.63M	103,227,518	2.26%	0.00%
ISPC	ISPECIMEN INC	$3.20M	2,496,858	0.55%	99.45%
PRE	PRENETICS GLOBAL LTD	$67.91M	12,984,844	8.77%	0.00%
NDRA	ENDRA LIFE SCIENCES INC	$4.05M	562,213	0.01%	99.99%	Net Buying

Diagnostic & Research Stocks FAQ

What are the best diagnostic & research stocks to buy right now in May 2025?

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best diagnostic & research stocks to buy right now are:

1. Qiagen Nv (NYSE:QGEN)

Qiagen Nv (NYSE:QGEN) is the #1 top diagnostic & research stock out of 58 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Qiagen Nv (NYSE:QGEN) is: Value: B, Growth: C, Momentum: C, Sentiment: C, Safety: C, Financials: B, and AI: C.

Qiagen Nv (NYSE:QGEN) has a Due Diligence Score of 23, which is -4 points lower than the diagnostic & research industry average of 27. Although this number is below the industry average, our proven quant model rates QGEN as a "A".

QGEN passed 9 out of 38 due diligence checks and has weak fundamentals. Qiagen Nv has seen its stock lose -1.42% over the past year, overperforming other diagnostic & research stocks by 24 percentage points.

Qiagen Nv has an average 1 year price target of $48.25, an upside of 14.34% from Qiagen Nv's current stock price of $42.20.

Qiagen Nv stock has a consensus Buy recommendation according to Wall Street analysts. Of the 4 analysts covering Qiagen Nv, 25% have issued a Strong Buy rating, 0% have issued a Buy, 75% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Illumina (NASDAQ:ILMN)

Illumina (NASDAQ:ILMN) is the #2 top diagnostic & research stock out of 58 with a Zen Rating of B. Stocks with a rating of B have had an average return of +19.88% per year. Learn more.

The Component Grade breakdown for Illumina (NASDAQ:ILMN) is: Value: B, Growth: A, Momentum: F, Sentiment: C, Safety: B, Financials: B, and AI: C.

Illumina (NASDAQ:ILMN) has a Due Diligence Score of 16, which is -11 points lower than the diagnostic & research industry average of 27. Although this number is below the industry average, our proven quant model rates ILMN as a "B".

ILMN passed 5 out of 33 due diligence checks and has weak fundamentals. Illumina has seen its stock lose -38.63% over the past year, underperforming other diagnostic & research stocks by -13 percentage points.

Illumina has an average 1 year price target of $129.17, an upside of 68.82% from Illumina's current stock price of $76.51.

Illumina stock has a consensus Buy recommendation according to Wall Street analysts. Of the 12 analysts covering Illumina, 33.33% have issued a Strong Buy rating, 8.33% have issued a Buy, 50% have issued a hold, while 0% have issued a Sell rating, and 8.33% have issued a Strong Sell.

3. Agilent Technologies (NYSE:A)

Agilent Technologies (NYSE:A) is the #3 top diagnostic & research stock out of 58 with a Zen Rating of B. Stocks with a rating of B have had an average return of +19.88% per year. Learn more.

The Component Grade breakdown for Agilent Technologies (NYSE:A) is: Value: B, Growth: C, Momentum: D, Sentiment: C, Safety: A, Financials: B, and AI: B.

Agilent Technologies (NYSE:A) has a Due Diligence Score of 47, which is 20 points higher than the diagnostic & research industry average of 27.

A passed 17 out of 38 due diligence checks and has strong fundamentals. Agilent Technologies has seen its stock lose -23.24% over the past year, overperforming other diagnostic & research stocks by 2 percentage points.

Agilent Technologies has an average 1 year price target of $141.86, an upside of 33.25% from Agilent Technologies's current stock price of $106.46.

Agilent Technologies stock has a consensus Buy recommendation according to Wall Street analysts. Of the 7 analysts covering Agilent Technologies, 14.29% have issued a Strong Buy rating, 14.29% have issued a Buy, 71.43% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the diagnostic & research stocks with highest dividends?

Out of 5 diagnostic & research stocks that have issued dividends in the past year, the 3 diagnostic & research stocks with the highest dividend yields are:

1. Quest Diagnostics (NYSE:DGX)

Quest Diagnostics (NYSE:DGX) has an annual dividend yield of 1.3%, which is 1 percentage points higher than the diagnostic & research industry average of 0.59%. Quest Diagnostics's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Quest Diagnostics's dividend has shown consistent growth over the last 10 years.

Quest Diagnostics's dividend payout ratio of 38.1% indicates that its dividend yield is sustainable for the long-term.

2. Agilent Technologies (NYSE:A)

Agilent Technologies (NYSE:A) has an annual dividend yield of 0.68%, which is the same as the diagnostic & research industry average of 0.59%. Agilent Technologies's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Agilent Technologies's dividend has shown consistent growth over the last 10 years.

Agilent Technologies's dividend payout ratio of 21.9% indicates that its dividend yield is sustainable for the long-term.

3. Labcorp Holdings (NYSE:LH)

Labcorp Holdings (NYSE:LH) has an annual dividend yield of 0.6%, which is the same as the diagnostic & research industry average of 0.59%. Labcorp Holdings's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Labcorp Holdings's dividend has not shown consistent growth over the last 10 years.

Labcorp Holdings's dividend payout ratio of 33% indicates that its dividend yield is sustainable for the long-term.

Why are diagnostic & research stocks down?

Diagnostic & research stocks were down -0.32% in the last day, and up 0.1% over the last week. Icon was the among the top losers in the diagnostics & research industry, dropping -4.11% yesterday.

Icon shares are trading lower after the company reported worse-than-expected Q1 sales results. Also, the company lowered its FY25 guidance.

What are the most undervalued diagnostic & research stocks?

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued diagnostic & research stocks right now are:

1. Icon (NASDAQ:ICLR)

Icon (NASDAQ:ICLR) is the most undervalued diagnostic & research stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Icon has a valuation score of 57, which is 39 points higher than the diagnostic & research industry average of 18. It passed 4 out of 7 valuation due diligence checks.

Icon's stock has dropped -51.86% in the past year. It has underperformed other stocks in the diagnostic & research industry by -26 percentage points.

2. Charles River Laboratories International (NYSE:CRL)

Charles River Laboratories International (NYSE:CRL) is the second most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Charles River Laboratories International has a valuation score of 14, which is -4 points higher than the diagnostic & research industry average of 18. It passed 1 out of 7 valuation due diligence checks. Although this number is below the industry average, our proven quant model rates CRL a Valuation Rating of "B".

Charles River Laboratories International's stock has dropped -49.77% in the past year. It has underperformed other stocks in the diagnostic & research industry by -24 percentage points.

3. Qiagen Nv (NYSE:QGEN)

Qiagen Nv (NYSE:QGEN) is the third most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Qiagen Nv has a valuation score of 14, which is -4 points higher than the diagnostic & research industry average of 18. It passed 1 out of 7 valuation due diligence checks. Although this number is below the industry average, our proven quant model rates QGEN a Valuation Rating of "B".

Qiagen Nv's stock has dropped -1.42% in the past year. It has overperformed other stocks in the diagnostic & research industry by 24 percentage points.

Are diagnostic & research stocks a good buy now?

51.22% of diagnostic & research stocks rated by analysts are a strong buy right now. On average, analysts expect diagnostic & research stocks to rise by 26.52% over the next year.

2.33% of diagnostic & research stocks have a Zen Rating of A (Strong Buy), 6.98% of diagnostic & research stocks are rated B (Buy), 81.4% are rated C (Hold), 9.3% are rated D (Sell), and 0% are rated F (Strong Sell).

What is the average p/e ratio of the diagnostics & research industry?

The average P/E ratio of the diagnostics & research industry is 39.08x.

WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.